Drug Trial Radar · NCT06799845
Phase 2B Study Assessing Pain Relief After Replacement of the Knee
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
226
Actual
Start
Feb 3, 2025
Primary completion
Oct 3, 2025
Study completion Oct 3, 2025
Sponsor
- Lead sponsor
- Allay Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the ATX101-TKA-004 clinical trial aims to evaluate the efficacy and safety of ATX101 1,500 mg in participants undergoing primary unilateral total knee arthroplasty. The study will compare the effectiveness of ATX101 with a saline placebo and bupivacaine, an active comparator. Additionally, it will assess opioid consumption among participants receiving ATX101 versus those given the saline placebo and bupivacaine. The trial will also focus on the safety and tolerability of ATX101 in the participants.
Conditions
- Total Knee Arthroplasty (Postoperative Pain)
Interventions
ATX101Drug
ATX101 bupivacaine implants, total of 1,500 mg into the surgical site
bupivacaine hydrochlorideDrug
bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration
saline placeboDrug
normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of Pain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to PlaceboTime frame: from 30 minutes through 168 hours (Day 8)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Woodland International Research Group, LLC
Little Rock, Arkansas
Phoenix Clinical Research
Tamarac, Florida
Atlanta Centre for Medical Research
Atlanta, Georgia
NextStage Clinical Research
Wichita, Kansas
Chesapeake Research Group, LLC
Pasadena, Maryland
First Surgical Hospital
Bellaire, Texas
Legent Orthopedic Hospital
Carrollton, Texas
Memorial Hermann Village
Houston, Texas
Endeavor Clinical Trials, LLC
San Antonio, Texas
NextStage Clinical Research
San Antonio, Texas
JBR Clinical Research, LLC
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.